Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Oct;87(20):7898–7901. doi: 10.1073/pnas.87.20.7898

Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

T Waddell 1, A Cohen 1, C A Lingwood 1
PMCID: PMC54858  PMID: 2236008

Abstract

Verotoxin 1 is an Escherichia coli-derived subunit toxin that specifically binds to the glycolipid globotriosylceramide and is cytotoxic for cells that contain this plasma membrane glycolipid. Glycolipid incorporation experiments have now been performed using human lymphoid cells of the B lineage that lack this receptor, to conclusively demonstrate that globotriosylceramide alone is a functional receptor for this toxin. Globotriosylceramide incorporated into the membrane of toxin-resistant cells provides intracellular access to verotoxin by receptor-mediated endocytosis. Protein synthesis is then inhibited and globotriosylceramide-containing cells are killed.

Full text

PDF
7898

Images in this article

7899Image
on p.7899
7900Image
on p.7900

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett T. J., Potter M. E., Wachsmuth I. K. Continuous peritoneal infusion of Shiga-like toxin II (SLT II) as a model for SLT II-induced diseases. J Infect Dis. 1989 Apr;159(4):774–777. doi: 10.1093/infdis/159.4.774. [DOI] [PubMed] [Google Scholar]
  2. Bennett V., Cuatrecasas P. Mechanism of activation of adenylate cyclase by Vibrio cholerae enterotoxin. J Membr Biol. 1975 Jun 3;22(1):29–52. doi: 10.1007/BF01868162. [DOI] [PubMed] [Google Scholar]
  3. Boyd B., Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nephron. 1989;51(2):207–210. doi: 10.1159/000185286. [DOI] [PubMed] [Google Scholar]
  4. Bretscher M. S. Directed lipid flow in cell membranes. Nature. 1976 Mar 4;260(5546):21–23. doi: 10.1038/260021a0. [DOI] [PubMed] [Google Scholar]
  5. Cohen A., Hannigan G. E., Williams B. R., Lingwood C. A. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem. 1987 Dec 15;262(35):17088–17091. [PubMed] [Google Scholar]
  6. Cohen A., Madrid-Marina V., Estrov Z., Freedman M. H., Lingwood C. A., Dosch H. M. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990;2(1):1–8. doi: 10.1093/intimm/2.1.1. [DOI] [PubMed] [Google Scholar]
  7. Düzgüneş N., Wilschut J., Fraley R., Papahadjopoulos D. Studies on the mechanism of membrane fusion. Role of head-group composition in calcium- and magnesium-induced fusion of mixed phospholipid vesicles. Biochim Biophys Acta. 1981 Mar 20;642(1):182–195. doi: 10.1016/0005-2736(81)90148-6. [DOI] [PubMed] [Google Scholar]
  8. Eiklid K., Olsnes S. Interaction of Shigella shigae cytotoxin with receptors on sensitive and insensitive cells. J Recept Res. 1980;1(2):199–213. doi: 10.3109/10799898009044098. [DOI] [PubMed] [Google Scholar]
  9. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988 Jan 15;171(1-2):45–50. doi: 10.1111/j.1432-1033.1988.tb13756.x. [DOI] [PubMed] [Google Scholar]
  10. Fong J. S., de Chadarevian J. P., Kaplan B. S. Hemolytic-uremic syndrome. Current concepts and management. Pediatr Clin North Am. 1982 Aug;29(4):835–856. doi: 10.1016/s0031-3955(16)34216-x. [DOI] [PubMed] [Google Scholar]
  11. Hansson H. A., Holmgren J., Svennerholm L. Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3782–3786. doi: 10.1073/pnas.74.9.3782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hui M. F., Lam P., Dosch H. M. Properties and heterogeneity of human fetal pre-B cells transformed by EBV. J Immunol. 1989 Oct 15;143(8):2470–2479. [PubMed] [Google Scholar]
  13. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., Keusch G. T. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med. 1986 Jun 1;163(6):1391–1404. doi: 10.1084/jem.163.6.1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985 May;151(5):775–782. doi: 10.1093/infdis/151.5.775. [DOI] [PubMed] [Google Scholar]
  15. Law H., Itkonnen O., Lingwood C. A. Sulfogalactolipid binding protein SLIP 1: a conserved function for a conserved protein. J Cell Physiol. 1988 Dec;137(3):462–468. doi: 10.1002/jcp.1041370310. [DOI] [PubMed] [Google Scholar]
  16. Lindberg A. A., Brown J. E., Strömberg N., Westling-Ryd M., Schultz J. E., Karlsson K. A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem. 1987 Feb 5;262(4):1779–1785. [PubMed] [Google Scholar]
  17. Lingwood C. A., Law H., Richardson S., Petric M., Brunton J. L., De Grandis S., Karmali M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987 Jun 25;262(18):8834–8839. [PubMed] [Google Scholar]
  18. Ludwig D. S., Ribi H. O., Schoolnik G. K., Kornberg R. D. Two-dimensional crystals of cholera toxin B-subunit-receptor complexes: projected structure at 17-A resolution. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8585–8588. doi: 10.1073/pnas.83.22.8585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Moss J., Fishman P. H., Manganiello V. C., Vaughan M., Brady R. O. Functional incorporation of ganglioside into intact cells: induction of choleragen responsiveness. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1034–1037. doi: 10.1073/pnas.73.4.1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. O'Brien A. D., LaVeck G. D. Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun. 1983 May;40(2):675–683. doi: 10.1128/iai.40.2.675-683.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Obrig T. G., Del Vecchio P. J., Brown J. E., Moran T. P., Rowland B. M., Judge T. K., Rothman S. W. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988 Sep;56(9):2373–2378. doi: 10.1128/iai.56.9.2373-2378.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Obrig T. G., Del Vecchio P. J., Karmali M. A., Petric M., Moran T. P., Judge T. K. Pathogenesis of haemolytic uraemic syndrome. Lancet. 1987 Sep 19;2(8560):687–687. doi: 10.1016/s0140-6736(87)92473-1. [DOI] [PubMed] [Google Scholar]
  23. Roberts D. D. Sulfatide-binding proteins. Chem Phys Lipids. 1986 Dec 15;42(1-3):173–183. doi: 10.1016/0009-3084(86)90051-4. [DOI] [PubMed] [Google Scholar]
  24. Sandvig K., Olsnes S., Brown J. E., Petersen O. W., van Deurs B. Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. J Cell Biol. 1989 Apr;108(4):1331–1343. doi: 10.1083/jcb.108.4.1331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Scotland S. M., Smith H. R., Rowe B. Two distinct toxins active on Vero cells from Escherichia coli O157. Lancet. 1985 Oct 19;2(8460):885–886. doi: 10.1016/s0140-6736(85)90146-1. [DOI] [PubMed] [Google Scholar]
  26. Strasberg P., Grey A., Warren I., Skomorowski M. A. Simultaneous fractionation of four placental neutral glycosphingolipids with a continuous gradient. J Lipid Res. 1989 Jan;30(1):121–127. [PubMed] [Google Scholar]
  27. Strockbine N. A., Marques L. R., Holmes R. K., O'Brien A. D. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun. 1985 Dec;50(3):695–700. doi: 10.1128/iai.50.3.695-700.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Strockbine N. A., Marques L. R., Newland J. W., Smith H. W., Holmes R. K., O'Brien A. D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun. 1986 Jul;53(1):135–140. doi: 10.1128/iai.53.1.135-140.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Unravelling HUS. Lancet. 1987 Dec 19;2(8573):1437–1439. [PubMed] [Google Scholar]
  30. Waddell T., Head S., Petric M., Cohen A., Lingwood C. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun. 1988 Apr 29;152(2):674–679. doi: 10.1016/s0006-291x(88)80091-3. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES